REFRACTORY ACUTE MYELOID LEUKEMIA

This early-phase study is testing the safety and best doses of a drug called palbociclib, given alone and in combination with other medications, for adults with acute leukemia that has returned or not responded to previous treatments. The main goal is to find the highest dose pat…

This early-stage study is testing the safety and best dose of a new drug called uproleselan when given with two standard chemotherapy drugs (fludarabine and cytarabine). It is for children and teenagers (ages 1-17) whose acute myeloid leukemia, myelodysplastic syndrome, or mixed …

This early-stage study is testing the safety and best dose of a new drug, nintedanib, when combined with an existing drug, azacitidine. It is for older adults with a specific type of acute myeloid leukemia (AML) who are not candidates for or choose not to have intensive chemother…

This early-stage trial is testing the safety and best dose of a combination of two oral drugs, enasidenib and cobimetinib, for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study is specifically for patients whose cancer has t…

This study is testing whether adding a drug called veliparib to a standard two-drug chemotherapy regimen works better for treating advanced blood cancers. It involves 25 adults with specific types of leukemia and related disorders that have progressed or are hard to treat. Partic…

This early-stage study is testing a new combination of three drugs—navtemadlin, decitabine, and venetoclax—for adults with acute myeloid leukemia (AML). The main goals are to find the safest dose and understand the side effects. The hope is that using all three drugs together wil…

This early-stage study is testing the safety and best dose of a two-drug combination for patients with advanced myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The trial combines a chemotherapy drug (decitabine…

This study is testing whether combining two chemotherapy drugs is safe and effective for treating adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or hasn't responded to other treatments. The goal is to control the disease, p…

This study is testing whether taking two oral medications together—venetoclax and ASTX727—can help control acute myeloid leukemia (AML), a type of blood cancer. It is for adults whose AML has come back or hasn't responded to prior treatment, or for older or less-fit adults newly …

This early-stage study is testing a new type of CAR T-cell therapy for adults with acute myeloid leukemia (AML) or a related blood cancer that has come back or not responded to other treatments. Doctors take a patient's or a donor's immune cells, genetically modify them to better…

This early-stage study is testing a new oral drug, M3814, when given alongside a standard chemotherapy regimen (MEC) for adults with acute myeloid leukemia (AML) that has come back or is not responding to other treatments. The main goals are to find the safest and most effective …

This early-stage trial is testing a new immunotherapy drug called flotetuzumab in children, teens, and young adults whose acute myeloid leukemia (AML) has come back or hasn't responded to other treatments. The main goals are to find the safest dose and understand the side effects…

This early-stage study is testing whether two drugs—entrectinib and ASTX727—can be safely combined to treat acute myeloid leukemia (AML) that has returned or resisted treatment and has a specific genetic change (TP53 mutation). The trial involves about 13 adults and aims to find …

This study is testing whether combining three different cancer drugs can better control two aggressive types of blood cancer: Philadelphia chromosome-positive acute myeloid leukemia (AML) and advanced chronic myeloid leukemia (CML). The trial will enroll about 20 adults with thes…

This study is testing whether two oral cancer drugs, venetoclax and decitabine, can help control a fast-growing blood cancer called acute myeloid leukemia (AML) in adults for whom prior treatments have stopped working. The goal is to see if this combination can reduce cancer cell…

This study is testing a drug called enasidenib in children and young adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to standard chemotherapy. The goal is to see if the drug is safe for children and how their bodies process it. The …

This study is testing if a pill called olaparib can help control advanced blood cancers (acute myeloid leukemia or myelodysplastic syndrome) that have come back or haven't responded to standard treatments. It is for adults whose cancer has a specific genetic change called an IDH …

This study is testing if adding the drug sorafenib to standard chemotherapy drugs (busulfan and fludarabine) is safe and effective for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The goal is to better prepare patients for a stem cell …

This early-stage study is testing the safety and best dose of a new three-drug combination for adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to prior treatments. The goal is to see if adding the drug regorafenib to two exis…

This study is testing a new combination of oral drugs (selinexor and venetoclax) with standard chemotherapy for children and young adults whose acute myeloid leukemia (AML) has returned or hasn't responded to previous treatments. The main goal is to find the safest and most effec…